TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Pain sensitivity measured by Cold Pressor Test (CPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain sensitivity measured by Short form of the McGill Pain Questionnaire (SF-MPQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Sedentary Behavior at 2 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Sedentary Behavior at 5 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in eosinophils per HPF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in aggressive behavior
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Postoperative analgesic effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative analgesic effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of grade 3-5 SAE occurring within 30 days of CD19CAR T-cell infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of grade 3-4 Severe Cytokine Release Syndrome following CD19 CAR T-cell infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of grade 3-5 neurotoxicity occurring within 30 days of CD19 CAR T-cell infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients in MRD-negative remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Hematologic outcomes
Primary endpoint: Proportion of patients in hematologic remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Hematologic outcomes
Primary endpoint: Oseltamivir carboxylate Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oseltamivir carboxylate AUC (0-12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Adverse Events/Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Intracellular steady-state concentrations of abacavir and lamivudine anabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intracellular half-lives of abacavir and lamivudine anabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined overall mortality
Endpoint domain: Mortality/survival
Primary endpoint: Stroke or procedure-related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Score on Objective Structured Clinical Exam (OSCE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: apparent total clearance (CL/F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma level of adrenaline in response to hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: State rumination
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: incidence, type and severity of adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Change in mock job interview
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in Cardiac Index (CI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in number of binge days per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mutation profile of ctDNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximum Oxygen Uptake (VO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carbon Dioxide Production (VCO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minute Ventilation (VE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timeline Follow-Back (TLFB)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Difference in Incontinence Impact Questionnaire (IIQ-7) scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Difference in Overactive Bladder Symptom Score (OABSS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Urogenital Distress Inventory (UDI-6) scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perfusion activity in the Limbic System
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Analysis of the viral genome by PCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analysis of the presence of capsid protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients who gain weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of diabetic patients having diabetic nephropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of new MS T2 lesion formation on brain MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Horizontal Jumping Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vertical Jumping Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COAST score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of major cardiovascular events (3-point MACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Transthoracic echocardiography results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Allergenicity of modified grass/rye pollen allergoid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Global Eating Pathology
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: episodes of postoperative vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: major complication
Endpoint domain: Adverse events/effects
Primary endpoint: Complete Healing of Erosive Esophagitis by Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change from Baseline Visceral adipose tissue (VAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Quadriceps Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Inflammatory biomarkers in CVA patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Thermogram of head
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for knee manipulation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Summed Richmond Agitation Sedation Score (RASS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of infectious diseases
Endpoint domain: Adverse events/effects
Primary endpoint: Efflux ratio (with enzalutamide)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efflux ratio (with enzalutamide and positive control)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance of Benralizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Serum Concentration-Time Curve From Time Zero to Day 28 (AUC0-28) of Benralizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Peripheral Blood Eosinophil Count up to Week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: oxidative stress status of seminal plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mental Well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Effect of vitamin C on iron chelation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Participant Lean Body Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Bilateral Leg Press (BLP) Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper gastrointestinal (UGI) safety and tolerability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Prevalence of obstructive sleep apnea hypopnea syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Prevalence Rate of Insulin Resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Neuroleptic Induced Deficit Syndromes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical effects of Systane and Refresh Tears
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in clinical eliciting dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of Clinically Significant Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QT/QTc Interval Analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time of pubertal growth spurt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Survival at Day 29
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants With Hemoglobin A1c (HbA1c) Reduction Greater Than or Equal to (>=) 0.4 Percent (%) and no Increase in Body Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cytokine assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Recipient with primary graft dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Reaching a Score Equal or Lower Than 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total 6-hour sodium output
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of limitations of activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Degree of limitation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change From Baseline in Weekly Average of Daily Trough Morning Peak Expiratory Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of time of interstitial glucose concentrations spent between 4.0-10.0 mmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: area under the curve of the receiver operator curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: predictive accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: true positive prediction rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: false positive prediction rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of treatment-related toxicity during preoperative therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Change in Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical sepsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time of anesthesiologist's presence
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: AUC of fimasartan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of fimasartan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of Linagliptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visit adherence rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Voice analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hormones measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in KOOS function (sports and recreational activities)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in volume fill of cartilage defect score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evidence of Anterior Chamber Inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: Change in caregivers
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Survival time after intervention
Endpoint domain: Mortality/survival
Primary endpoint: Plasma (R-) and (S-) methadone concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum amprenavir concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CD4 Count From Baseline to Follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in CD8 Count From Baseline to Follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Absolute Neutrophil Count From Baseline to Follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Platelet Count From Baseline to Follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Creatinine Count From Baseline to Follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: RNA expression profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of bladder perforation
Endpoint domain: Adverse events/effects
Primary endpoint: rate of post-operative pain
Endpoint domain: Adverse events/effects
Primary endpoint: scar height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute kidney injury occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: HCMV non-primary infection
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Absolute Gluconeogenesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Facial emotion recognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Theory of mind - Verbal task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Theory of mind - Contextual task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Participants With at Least a 2-point Improvement in NAFLD Activity Score (NAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients who suffer at least one adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Intrahospital mortality from any cause
Endpoint domain: Mortality/survival
Primary endpoint: Postprandial Glucose Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Actual Sampling Time to Reach the Maximum Observed Plasma Analyte Concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: De Morton Mobility Index (DEMMI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Measurement of inflammatory biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Teacher Use of Active Learning Methods (Observed)
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Change in Teacher Use of Active Learning Methods (Self-reported)
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Change in Classroom Level of Student Engagement (Observed)
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Retinal vascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness
Endpoint domain: Physiological/clinical
Primary endpoint: Fade on Train of Four Stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Number of Inflammatory Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Cross-sectional area (CSA) of intrinsic foot muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in muscle activity and timing of Electromyography (EMG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Balance stability margin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine Culture Examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Treatment success in clinically suspected UTI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Vascular access complication rate
Endpoint domain: Adverse events/effects
Primary endpoint: Differences in neurocognitive assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences in functional brain imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences in structural brain imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence (hours/night)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Anxiety Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Gastromucosal Damage (GMD) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Severity of muscle atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Severity of stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Clinical Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of conversion to general anesthesia
Endpoint domain: Adverse events/effects
Primary endpoint: ECG monitoring results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cmax for baseline-adjusted total iron and transferrin-bound iron
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t for baseline-adjusted total iron and transferrin-bound iron
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cold sensitivity assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor blockade assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cure rate of AGI
Endpoint domain: Mortality/survival
Primary endpoint: remission rate of AGI
Endpoint domain: Mortality/survival
Primary endpoint: Reproducible motor evoked potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Susceptibility to SARS-COV-2 infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Primary patency of the operated segment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Proportion of subjects with serotype-specific pneumococcal IgG antibody concentration ≥ 0.35 ug/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric mean concentration (GMC) of serotype-specific pneumococcal IgG antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of referrals to physical therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Hospitalization for recurrent symptomatic myocardial ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: TRR75
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Blood Loss After Operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of Membranous Nephropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Intraabdominal volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in ADP-induced Platelet Aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Knowledge about COPD control and self-management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: tumor metabolic response
Endpoint domain: Mortality/survival
Primary endpoint: plasma EBV DNA half-life
Endpoint domain: Mortality/survival
Primary endpoint: Overall Acute Graft-Versus-Host Disease (GVHD) Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of Complete Remission/Complete Remission With Incomplete Recovery of the Bone Marrow (CR/CRi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Hematological outcomes
Primary endpoint: Device explantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes